Helsinn Group, of Lugano, Switzerland, and Mundipharma Pte. Ltd., of Singapore, signed an exclusive license and distribution agreement, covering China, Hong Kong and Macao, for netupitant-palonosetron fixed-dose combination (NEPA), a Helsinn product under development for the treatment of chemotherapy-induced nausea and vomiting.